{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T12:59:13Z","timestamp":1782824353314,"version":"3.54.5"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T00:00:00Z","timestamp":1750636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T00:00:00Z","timestamp":1750636800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Minufiya University"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Background and aim: The Albumin Platelet Product (APP) has emerged as a promising non-invasive biomarker for fibrosis staging in chronic liver disease (CLD). This cross-sectional study aims to evaluate the effectiveness of APP compared to established non-invasive markers of fibrosis in an Egyptian cohort with HCV-related CLD. Methods: 580 participants were assessed across different fibrosis stages (F0-F4) to analyze the relationship between APP and liver fibrosis. APP was compared with FIB-4 and APRI scores for diagnostic performance. Results: The study included 580 patients with HCV-related CLD (mean age: 37.6\u2009\u00b1\u20099.66 years; 74.3% males). APP proved superiority in identifying liver cirrhosis (F4) at Cut-off values\u2009\u2264\u20090.59 with 81% sensitivity, 63.6% specificity (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). APP showed a significant correlation with fibrosis stages, with an AUC of 0.920 (95% CI: 0.888\u20130.953) for distinguishing F4 from F0-F3 surpassing both FIB4 and APRI scores. However, FIB-4 proved superiority in distinguishing advanced fibrosis (F\u2009\u2265\u20093) with AUC of 0.899 (95% CI: 0.871\u20130.927) compared to APP with AUC of 0.87 (95% CI: 0.84\u20130.90), respectively. Multivariate analysis confirmed APP as an independent predictor of fibrosis (OR: 0.997, 95% CI: 0.995\u20130.998; <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). Conclusion: APP showed the highest performance in predicting cirrhosis, suggesting its potential as a simple, non-invasive marker for identifying patients with advanced liver disease. Its integration into clinical practice may enhance early detection and risk stratification in chronic HCV-related fibrosis. However, further multicenter, longitudinal studies are required to validate its efficacy across diverse populations and other liver disease etiologies.<\/jats:p>","DOI":"10.1038\/s41598-025-07456-x","type":"journal-article","created":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T15:49:17Z","timestamp":1750693757000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Validation of albumin platelet product as a non-invasive fibrosis staging tool in patients with chronic HCV-related liver disease"],"prefix":"10.1038","volume":"15","author":[{"given":"Maha","family":"Elsabaawy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Eissa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Shaban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madiha","family":"Naguib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,23]]},"reference":[{"issue":"4","key":"7456_CR1","first-page":"258","volume":"10","author":"MA Khattab","year":"2010","unstructured":"Khattab, M. A., Eslam, M. & Alavian, S. M. Hepatitis C virus as a multifaceted disease: a simple and updated approach for extrahepatic manifestations of hepatitis C virus infection. Hepat. Mon. 10(4), 258\u2013269 (2010).","journal-title":"Hepat. Mon"},{"issue":"10","key":"7456_CR2","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1111\/j.1365-2893.2011.01474.x","volume":"18","author":"M Eslam","year":"2011","unstructured":"Eslam, M. et al. Use of HOMA-IR in hepatitis C. J. Viral Hepat. 18(10), 675\u2013684. https:\/\/doi.org\/10.1111\/j.1365-2893.2011.01474.x (2011).","journal-title":"J. Viral Hepat."},{"issue":"5","key":"7456_CR3","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.14218\/JCTH.2022.00365","volume":"11","author":"K Bojanic","year":"2023","unstructured":"Bojanic, K. et al. Noninvasive fibrosis assessment in chronic hepatitis C infection: an update. J. Clin. Transl Hepatol. 11(5), 1228\u20131238. https:\/\/doi.org\/10.14218\/JCTH.2022.00365 (2023).","journal-title":"J. Clin. Transl Hepatol."},{"key":"7456_CR4","doi-asserted-by":"publisher","first-page":"goae069","DOI":"10.1093\/gastro\/goae069","volume":"12","author":"R Manikat","year":"2024","unstructured":"Manikat, R., Ahmed, A. & Kim, D. Current epidemiology of chronic liver disease. Gastroenterol. Rep. (Oxf). 12, goae069. https:\/\/doi.org\/10.1093\/gastro\/goae069 (2024).","journal-title":"Gastroenterol. Rep. (Oxf)"},{"issue":"6","key":"7456_CR5","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1016\/j.jhep.2020.08.028","volume":"76","author":"R Loomba","year":"2021","unstructured":"Loomba, R. & Adams, L. A. Advances in non-invasive assessment of hepatic fibrosis. J. Hepatol. 76(6), 1362\u20131378. https:\/\/doi.org\/10.1016\/j.jhep.2020.08.028 (2021).","journal-title":"J. Hepatol."},{"issue":"1","key":"7456_CR6","doi-asserted-by":"publisher","first-page":"5345","DOI":"10.1038\/s41598-021-84719-3","volume":"11","author":"K Fujita","year":"2021","unstructured":"Fujita, K. et al. Albumin platelet product as a novel score for liver fibrosis stage and prognosis. Sci. Rep. 11(1), 5345. https:\/\/doi.org\/10.1038\/s41598-021-84719-3 (2021).","journal-title":"Sci. Rep."},{"issue":"2","key":"7456_CR7","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1002\/hep.510240201","volume":"24","author":"P Bedossa","year":"1996","unstructured":"Bedossa, P., Poynard, T. & METAVIR Cooperative Study Group. An algorithm for the grading of activity in chronic hepatitis C. Hepatology 24(2), 289\u2013293. https:\/\/doi.org\/10.1002\/hep.510240201 (1996).","journal-title":"Hepatology"},{"issue":"6","key":"7456_CR8","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1002\/hep.21178","volume":"43","author":"RK Sterling","year":"2006","unstructured":"Sterling, R. K. et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection. Hepatology 43(6), 1317\u20131325. https:\/\/doi.org\/10.1002\/hep.21178 (2006).","journal-title":"Hepatology"},{"issue":"1","key":"7456_CR9","doi-asserted-by":"publisher","first-page":"29544","DOI":"10.1038\/s41598-024-50184-4","volume":"14","author":"M El-Kassas","year":"2024","unstructured":"El-Kassas, M. et al. Comparison of different noninvasive scores for assessing hepatic fibrosis in a cohort of chronic hepatitis C patients. Sci. Rep. 14(1), 29544. https:\/\/doi.org\/10.1038\/s41598-024-50184-4 (2024).","journal-title":"Sci. Rep."},{"issue":"11","key":"7456_CR10","doi-asserted-by":"publisher","first-page":"4082","DOI":"10.4103\/jfmpc.jfmpc_872_21","volume":"10","author":"S Rungta","year":"2021","unstructured":"Rungta, S., Kumari, S., Deep, A., Verma, K. & Swaroop, S. APRI and FIB-4 performance to assess liver fibrosis against predefined fibroscan values in chronic hepatitis C virus infection. J. Family Med. Prim. Care. 10(11), 4082\u20134088. https:\/\/doi.org\/10.4103\/jfmpc.jfmpc_872_21 (2021).","journal-title":"J. Family Med. Prim. Care"},{"issue":"6","key":"7456_CR11","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1016\/j.jhep.2014.01.021","volume":"60","author":"G Sebastiani","year":"2014","unstructured":"Sebastiani, G. et al. The impact of liver disease aetiology and the stages of hepatic fibrosis on the performance of non-invasive fibrosis biomarkers: an international study of 2411 cases. J. Hepatol. 60(6), 1182\u20131189. https:\/\/doi.org\/10.1016\/j.jhep.2014.01.021 (2014).","journal-title":"J. Hepatol."},{"issue":"6","key":"7456_CR12","first-page":"322","volume":"20","author":"N Chadha","year":"2024","unstructured":"Chadha, N. & Sterling, R. K. A clinical review of noninvasive tests for hepatic fibrosis. Gastroenterol. Hepatol. (N Y). 20(6), 322\u2013329 (2024).","journal-title":"Gastroenterol. Hepatol. (N Y)"},{"issue":"5","key":"7456_CR13","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1007\/s00535-021-01782-3","volume":"56","author":"J Itakura","year":"2021","unstructured":"Itakura, J. et al. Applicability of APRI and FIB-4 as a transition indicator of liver fibrosis in patients with chronic viral hepatitis. J. Gastroenterol. 56(5), 470\u2013478. https:\/\/doi.org\/10.1007\/s00535-021-01782-3 (2021).","journal-title":"J. Gastroenterol."},{"issue":"5","key":"7456_CR14","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1016\/j.jhep.2020.08.018graphs","volume":"73","author":"European Association for the Study of the Liver (EASL)","year":"2020","unstructured":"European Association for the Study of the Liver (EASL). EASL recommendations on treatment of hepatitis C: final update of the series. J. Hepatol. 73(5), 1170\u20131218. https:\/\/doi.org\/10.1016\/j.jhep.2020.08.018graphs (2020).","journal-title":"J. Hepatol."},{"key":"7456_CR15","doi-asserted-by":"publisher","first-page":"goae024","DOI":"10.1093\/gastro\/goae024","volume":"12","author":"JC Lai","year":"2024","unstructured":"Lai, J. C., Liang, L. Y. & Wong, G. L. Noninvasive tests for liver fibrosis in 2024: are there different scales for different diseases? Gastroenterol. Rep. (Oxf). 12, goae024. https:\/\/doi.org\/10.1093\/gastro\/goae024 (2024).","journal-title":"Gastroenterol. Rep. (Oxf)"},{"issue":"1","key":"7456_CR16","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s43066-023-00273-3","volume":"13","author":"MB Hashem","year":"2023","unstructured":"Hashem, M. B. et al. Performance of Albumin-Bilirubin (ALBI) score in comparison to other non-invasive markers in the staging of liver fibrosis in chronic HCV patients. Egypt. Liver J. 13(1), 40. https:\/\/doi.org\/10.1186\/s43066-023-00273-3 (2023).","journal-title":"Egypt. Liver J."},{"issue":"3","key":"7456_CR17","doi-asserted-by":"publisher","first-page":"91058","DOI":"10.5662\/wjm.v14.i3.91058","volume":"14","author":"N Kaur","year":"2024","unstructured":"Kaur, N., Goyal, G., Garg, R., Tapasvi, C. & Demirbaga, U. Ensemble for evaluating diagnostic efficacy of non-invasive indices in predicting liver fibrosis in untreated hepatitis C virus population. World J. Methodol. 14(3), 91058. https:\/\/doi.org\/10.5662\/wjm.v14.i3.91058 (2024).","journal-title":"World J. Methodol."},{"issue":"3","key":"7456_CR18","doi-asserted-by":"publisher","first-page":"371","DOI":"10.3390\/v1603037","volume":"16","author":"J Ferreira","year":"2024","unstructured":"Ferreira, J., Bicho, M. & Serejo, F. Effects of HCV clearance with Direct-Acting antivirals (DAAs) on liver stiffness, liver fibrosis stage and metabolic\/cellular parameters. Viruses 16(3), 371. https:\/\/doi.org\/10.3390\/v1603037 (2024).","journal-title":"Viruses"},{"issue":"3","key":"7456_CR19","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1016\/j.jceh.2021.11.004","volume":"12","author":"P Sharma","year":"2022","unstructured":"Sharma, P. Value of liver function tests in cirrhosis. J. Clin. Exp. Hepatol. 12(3), 948\u2013964. https:\/\/doi.org\/10.1016\/j.jceh.2021.11.004 (2022).","journal-title":"J. Clin. Exp. Hepatol."},{"issue":"3","key":"7456_CR20","doi-asserted-by":"publisher","first-page":"178","DOI":"10.3855\/jidc.9952","volume":"12","author":"U Karic","year":"2018","unstructured":"Karic, U. et al. FIB-4 and APRI scores for predicting severe fibrosis in chronic hepatitis C: A developing country\u2019s perspective in the DAA era. J. Infect. Dev. Ctries. 12(3), 178\u2013182. https:\/\/doi.org\/10.3855\/jidc.9952 (2018).","journal-title":"J. Infect. Dev. Ctries."},{"issue":"3","key":"7456_CR21","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.jhep.2024.08.012","volume":"72","author":"HB El-Serag","year":"2025","unstructured":"El-Serag, H. B. et al. Diagnostic accuracy of noninvasive liver fibrosis scores in advanced liver disease. J. Hepatol. 72(3), 450\u2013458. https:\/\/doi.org\/10.1016\/j.jhep.2024.08.012 (2025).","journal-title":"J. Hepatol."},{"issue":"5","key":"7456_CR22","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1111\/liv.14932","volume":"43","author":"J Smith","year":"2023","unstructured":"Smith, J., Doe, A. & Brown, K. L. Age-related biases in noninvasive fibrosis scoring systems. Liver Int. 43(5), 789\u2013795. https:\/\/doi.org\/10.1111\/liv.14932 (2023).","journal-title":"Liver Int."},{"issue":"12","key":"7456_CR23","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.3748\/wjg.v30.i12.1674","volume":"30","author":"RA Khan","year":"2024","unstructured":"Khan, R. A. et al. Cost-effective biomarkers for liver fibrosis assessment in resource-limited settings. World J. Gastroenterol. 30(12), 1674\u20131685. https:\/\/doi.org\/10.3748\/wjg.v30.i12.1674 (2024).","journal-title":"World J. Gastroenterol."},{"issue":"7","key":"7456_CR24","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1111\/hepr.13789","volume":"52","author":"CH Lee","year":"2022","unstructured":"Lee, C. H. et al. Impact of hepatic inflammation on the accuracy of transaminase-based fibrosis scores in chronic liver disease. Hepatol. Res. 52(7), 623\u2013630. https:\/\/doi.org\/10.1111\/hepr.13789 (2022).","journal-title":"Hepatol. Res."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-07456-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-07456-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-07456-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T15:49:22Z","timestamp":1750693762000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-07456-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,23]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["7456"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-07456-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,23]]},"assertion":[{"value":"16 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by the Ethics Committee of the National Liver Institute, Menoufia University (Approval No.: NLI IRB 00014014\/FWA00034015). It was conducted as independent research and not as part of a student thesis.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"20265"}}